Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT201 and Teraplizumab in Non-small Cell Lung Cancer
NCT06235242Terminated
- Sponsor
- Grit Biotechnology
- Start
- Feb 2024
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Gene Silencing, Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Open-label, single-arm trial of GT201 in non-small cell lung cancer (NSCLC), sponsored by Grit Biotechnology. Primary endpoint: Safety Profile Measured by Grade ≥3 Treatment-Related Adverse Events at 3 years. Started Feb 2024; status: terminated.
02
Drugs
GT201
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06235242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06235242.